TS03 Inc Trust Units TSTIF

RE:RE:RE:RE:RE:RE:RE:RE:Well looks like we are down to the last day!!!!

[Xwing229]

P.10
https://www.tso3.com/wp-content/uploads/2018/06/Q1-2018-Report.pdf


The capital equipment sales process in the medical device industry remains slow relative to other industries, but the Company is making progress. The Company made progress on a direct sales basis in the first quarter of 2018, and, based on customer feedback the Company has received, TSO3 is able to provide sales and customer support at industry leading levels. It has successfully segmented and classified its target customer base, has contacted 531 of these customers, and directly issued quotations to US medical facilities for over 30 STERIZONE® VP4 Sterilizers, plus associated accessories and consumables. Each quotation is now being managed through the Company’s funnel management process. Additionally, the Company has devised new and innovative sales incentives and structures to match customer feedback. The Company is involved in direct communication, industry events, and other customer outreach activities. Additionally, we believe that Getinge sold and installed fewer than 10 STERIZONE® VP4 Sterilizers in the first quarter of 2018, which was below Getinge’s and TSO3’s expectations. TSO3 is working with Getinge to improve this rate of sales toward a goal of exceeding installation rates of the previous year. Due to inventory levels at Getinge, the Company currently does not anticipate selling more STERIZONE® VP4 Sterilizers to Getinge throughout the remainder of 2018.